Quarterly net revenue from continuing operations up 25 percent sequentially Quarterly GAAP gross margin from continuing operations of 50 percent; Quarterly Non-GAAP gross margin from continuing operations of 58 percent Quarterly GAAP diluted EPS from continuing operations of $0.50; Quarterly Non-GAAP diluted EPS from continuing operations of $1.99
SAN JOSE, Calif.
GAAP gross margin from continuing operations of 31 percent; Non-GAAP gross margin from continuing operations of 57 percent GAAP diluted EPS loss of $0.65; Non-GAAP diluted EPS from continuing operations of $1.26 Fourth fiscal quarter revenue from continuing operations projected to be up 18-22% sequentially
SAN JOSE, Calif., and SINGAPORE, Aug.
Seppy Basili, Kaplan Test Prep’s vice president of college admissions
and K12 programs, is available to speak with interested journalists
regarding the company’s participation in today’s White House College
Opportunity Day of Action and Kaplan’s commitment to the First Lady’s
“Reach Higher” Campaign.
AvalonBay Communities, Inc. (NYSE: AVB) (the “Company”) announced
today that it priced a $300 million offering of unsecured notes (the
“Notes”) with a maturity of November 15, 2024 under its existing shelf
AvalonBay Communities, Inc. (NYSE: AVB) (the “Company”) reported today
Net Income Attributable to Common Stockholders for the quarter ended
September 30, 2014 of $241,100,000. This resulted in Earnings per Share
– diluted (“EPS”) of $1.83 for the three months ended September 30,
2014, compared to a loss of $0.08 per share for the comparable period of
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating
whether members of the board of directors of Avanir Pharmaceuticals,
Inc. (NASDAQ: AVNR) breached their fiduciary duties in connection with
the planned merger of the Company with Otsuka Pharmaceutical Co., Ltd.
Sign-up for Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease investment picks
Sign-up for Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.